Peregrine Pharmaceuticals reported $3.27M in EBIT for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Agenus AGEN:US $ -35997000 20.08M
Amgen AMGN:US $ 2500M 196M
AstraZeneca AZN:LN 2.88B 1.57B
Biocryst Pharmaceuticals BCRX:US $ -49957000 2.22M
Bristol Myers Squibb BMY:US $ 3188M 399M
Celldex Therapeutics CLDX:US $ -23257000 2.92M
Chemocentryx CCXI:US $ -38233000 1.82M
Eli Lilly And LLY:US $ 2569.9M 171.6M
GlaxoSmithKline GSK:LN 2.42B 724M
Immunogen IMGN:US $ -22852000 11.7M
Intrexon XON:US $ -17414000 3.07M
Karyopharm Therapeutics KPTI:US $ -34586000 81.55M
Macrogenics MGNX:US $ -66638000 8.4M
Mannkind MNKD:US $ -23239000 2.29M
Merk MRK:US $ 5059M 207M
Minerva Neurosciences NERV:US $ -7989260 13.39M
Newlink Genetics NLNK:US -7731000 1.16M
Novartis NOVN:VX 3.15B 266M
Novavax NVAX:US $ 209.29M 1.03B
Peregrine Pharmaceuticals PPHM:US $ 3.27M 884K
Repligen RGEN:US $ 60.78M 6.51M
Xencor XNCR:US $ 26.47M 65.19M